258 related articles for article (PubMed ID: 30194449)
1. Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome.
Shmueli MD; Levy-Kanfo L; Haj E; Schoenfeld AR; Gazit E; Segal D
Oncogene; 2019 Feb; 38(7):1038-1049. PubMed ID: 30194449
[TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
[TBL] [Abstract][Full Text] [Related]
4. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
5. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
6. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Knauth K; Bex C; Jemth P; Buchberger A
Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
[TBL] [Abstract][Full Text] [Related]
8. Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer.
Chakraborty AA
Semin Cancer Biol; 2020 Dec; 67(Pt 2):34-42. PubMed ID: 32209418
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
10. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
11. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
[TBL] [Abstract][Full Text] [Related]
12. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
13. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
Zhou L; Yang H
PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
[TBL] [Abstract][Full Text] [Related]
14. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
Kapitsinou PP; Haase VH
Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
[TBL] [Abstract][Full Text] [Related]
15. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
17. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
18. The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin.
Kumar V; Kaushik V; Kumar S; Levkovich SA; Gupta P; Laor Bar-Yosef D; Gazit E; Segal D
Biochem Biophys Res Commun; 2024 Jan; 690():149250. PubMed ID: 38039781
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
20. Computational and experimental characterization of dVHL establish a Drosophila model of VHL syndrome.
Shmueli MD; Schnaider L; Herzog G; Gazit E; Segal D
PLoS One; 2014; 9(10):e109864. PubMed ID: 25310726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]